The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment

2017 ◽  
Author(s):  
Tomaz Kocjan ◽  
Antonela Sabati Rajic ◽  
Mojca Jensterle Sever ◽  
Gaj Vidmar ◽  
Barbara Ostanek ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Teriparatide Treatment

scholarly journals Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study

2019 ◽  
Vol 48 (2) ◽  
pp. 030006051987674
Author(s):  
Tiansong Yang ◽  
Chuwen Feng ◽  
Yuanyuan Qu ◽  
Qingyong Wang ◽  
Yan Yang ◽  
...  
Keyword(s):  
Back Pain ◽  
Treatment Group ◽  
Postmenopausal Osteoporosis ◽  
Short Form ◽  
Life Quality ◽  
Control Group ◽  
Teriparatide Treatment ◽  
Sf 36 ◽  
Vas Scores

Objective To evaluate the effect of teriparatide on life quality in patients with postmenopausal osteoporosis. Methods Patients treated from January 2014 to December 2016 were retrospectively included. Patients were divided into two groups according the treatment received. Those in the teriparatide treatment group were followed up for 24 months, and patients in the control group received calcium supplements and vitamin D. Scores for back pain using a visual analog scale (VAS) and score of the Oswestry Disability Index (ODI) and 36-item Short Form Health Survey of life quality (SF-36) were evaluated at 3, 6, 12, and 24 months and compared between the groups. Results In total, 126 patients were included in the teriparatide treatment group and 127 in the control group. There were no significant differences between the groups concerning body mass index, bone density, VAS back pain score, ODI, and SF-36 life quality scores at baseline. At 3, 6, 12, and 24 months’ follow-up, VAS scores were significantly lower in the treatment group than in controls; ODI and SF-36 scores were significantly higher in the treatment group than in the control group. Conclusion Teriparatide can significantly decrease pain and increase mobility and life quality in patients with postmenopausal osteoporosis.

Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis

2021 ◽  
Author(s):  
Tomaz Kocjan ◽  
Antonela Sabati Rajic ◽  
Andrej Janez ◽  
Gaj Vidmar ◽  
Nina Orehek ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Teriparatide Treatment

Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis

2014 ◽  
Vol 21 (3) ◽  
pp. 425-431 ◽  
Author(s):  
Gen Inoue ◽  
Masaki Ueno ◽  
Toshiyuki Nakazawa ◽  
Takayuki Imura ◽  
Wataru Saito ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Pedicle Screws ◽  
Treated Group ◽  
Control Group ◽  
Fusion Surgery ◽  
Teriparatide Treatment ◽  
Significant Difference ◽  
Insertional Torque ◽  
The Mean

Object The object of this study was to examine the efficacy of preoperative teriparatide treatment for increasing the insertional torque of pedicle screws during fusion surgery in postmenopausal women with osteoporosis. Methods Fusion surgery for the thoracic and/or lumbar spine was performed in 29 postmenopausal women with osteoporosis aged 65–82 years (mean 72.2 years). The patients were divided into 2 groups based on whether they were treated with teriparatide (n = 13) or not (n = 16) before the surgery. In the teriparatide-treated group, patients received preoperative teriparatide therapy as either a daily (20 μg/day, n = 7) or a weekly (56.5 μg/week, n = 6) injection for a mean of 61.4 days and a minimum of 31 days. During surgery, the insertional torque was measured in 212 screws inserted from T-7 to L-5 and compared between the 2 groups. The correlation between the insertional torque and the duration of preoperative teriparatide treatment was also investigated. Results The mean insertional torque value in the teriparatide group was 1.28 ± 0.42 Nm, which was significantly higher than in the control group (1.08 ± 0.52 Nm, p < 0.01). There was no significant difference between the daily and the weekly teriparatide groups with respect to mean insertional torque value (1.34 ± 0.50 Nm and 1.18 ± 0.43 Nm, respectively, p = 0.07). There was negligible correlation between insertional torque and duration of preoperative teriparatide treatment (r2 = 0.05, p < 0.01). Conclusions Teriparatide injections beginning at least 1 month prior to surgery were effective in increasing the insertional torque of pedicle screws during surgery in patients with postmenopausal osteoporosis. Preoperative teriparatide treatment might be an option for maximizing the purchase of the pedicle screws to the bone at the time of fusion surgery.

scholarly journals Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?

2017 ◽  
Vol 11 (2) ◽  
pp. 272-277 ◽  
Author(s):  
Seiji Ohtori ◽  
Sumihisa Orita ◽  
Kazuyo Yamauchi ◽  
Yawara Eguchi ◽  
Yasuchika Aoki ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Degenerative Spondylolisthesis ◽  
Case Series ◽  
Posterolateral Fusion ◽  
Retrospective Case ◽  
Bone Fusion ◽  
Teriparatide Treatment ◽  
The Right ◽  
Mass Volume ◽  
Lumbar Posterolateral Fusion

<sec><title>Study Design</title><p>Retrospective case series.</p></sec><sec><title>Purpose</title><p>The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis.</p></sec><sec><title>Overview of Literature</title><p>Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years.</p></sec><sec><title>Methods</title><p>We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 µg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery.</p></sec><sec><title>Results</title><p>We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (<italic>p</italic>&gt;0.05).</p></sec><sec><title>Conclusions</title><p>This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis.</p></sec>

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Primary Outcome ◽  
Osteoporosis Treatment ◽  
Secondary Outcome ◽  
Matched Pairs ◽  
Fracture History ◽  
Baseline Characteristics ◽  
Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

Zoledronate in the treatment of postmenopausal osteoporosis

2007 ◽  
Vol 115 (S 1) ◽  
Author(s):  
H Stracke ◽  
S Wamsler ◽  
A Liebchen ◽  
RG Bretzel
Keyword(s):  
Postmenopausal Osteoporosis
Sign in / Sign up

Export Citation Format

Share Document